Developer docs
API playgroundTry for free, no card

Search company profiles

ALPS Global Holding Berhad

Full company profile

uuid0002tkh

Namestring
ALPS Global Holding Berhad
Legal namestring
ALPS Global Holding Berhad
Company typeenum
Public
Founded yearint
2015
Descriptiontext

ALPS Global Holding Berhad is a Kuala Lumpur-based, fully integrated biotechnology research, medical, and wellness services company that operates across predictive, preventive, and precision medicine. Through its wholly-owned subsidiaries, the group runs a cGMP-certified cell and gene therapy facility (CelestiaLab), an MS ISO 15189:2022 accredited molecular laboratory (MyGenome) for whole genome sequencing and related tests, a medical diagnostic and treatment centre (ALPS Medical Centre), a consumer stem-cell supplement brand (Célébre), a healthcare financial solutions unit (ALPSCap), and a vaccine-focused subsidiary (MontLife). Core technology assets include a patent-pending antibody-free NK cell culture protocol (Malaysian patent application PI2025002484) that enables cost-effective, large-scale production of autologous natural killer cells, alongside mesenchymal stem cell (MSC) and induced pluripotent stem cell (iPSC) capabilities.

The company monetizes through professional services across genomic testing and clinical care, one-time licenses/sales of GMP-grade cellular products and stem cell supplements, and managed services via ALPSCap's healthcare financial solutions for corporations, governments, and high-net-worth individuals. Go-to-market combines direct medical service delivery at its Kuala Lumpur and Genting Highlands facilities, medical tourism channels targeting international patients, and B2B partnerships with universities and government institutions, with a stated shift toward captive insurance models and university-affiliated programmes post-Nasdaq listing. Customer segments include patients seeking advanced treatments typically excluded from conventional healthcare, health-conscious individuals pursuing preventive genomic screening, international medical tourism clients, and corporate/institutional buyers of integrated health-wealth solutions.

Following a business combination with Globalink Investment Inc., the US parent (Alps Group Inc.) began trading on Nasdaq under ticker ALPS on October 31, 2025, at an implied enterprise value of approximately US$1.6 billion alongside a modest US$3.1M PIPE financing. The company is unprofitable, with approximately US$3.7M in trailing twelve-month revenue, and has seen its market capitalization decline to roughly US$162 million amid broader early-stage biotech investor caution, while pivoting commercially toward Bio Valley campuses in Johor and Kuala Lumpur, insurance and education verticals, and continued clinical validation of its NK cell pipeline.

Short descriptiontext

ALPS Global Holding Berhad is a Kuala Lumpur-based integrated biotechnology group operating cell and gene therapy manufacturing (CelestiaLab), genomic testing (MyGenome), medical and wellness services, stem cell supplements, and healthcare financial solutions, serving individual patients, medical tourists, and institutional clients in Southeast Asia following its October 2025 Nasdaq listing.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersKuala Lumpur, Malaysia
HQ citystring
Kuala Lumpur
HQ countrystring
Malaysia
HQ regionstring
Asia
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cellular therapy services, genomic sequencing testing, regenerative medicine research, medical wellness services, stem cell products
Industry2 codes
PRIMARYHLAGAGAA
Cell Therapy CDMO (Autologous/Allogeneic Manufacturing)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
SECONDARYHLAAALAD
Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics)
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
  • Food (Health) Supplement Retailers456191
SIC code4 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
  • Medicinal Chemicals & Botanical Products2833
  • Services-Medical Laboratories8071
Product category
Biotechnology and Regenerative Medicine
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model5 records
1Medical and Wellness Services
TypeProfessional Services
Description

Revenue from medical centres, anti-aging clinics, health screening services, and aesthetic treatments

alps-holdings.com
2Genomic Testing Services
TypeProfessional Services
Description

Whole genome sequencing, mRNA testing, DNA testing services provided through MyGenome subsidiary

alps-holdings.com
3Cellular Therapy Products
TypeOne Time License
Description

GMP-grade stem cell products including mesenchymal stem cells, dental pulp stem cells, and iPSCs for therapeutic applications

alps-holdings.com
4Stem Cell Supplements
TypeOne Time License
Description

Célebre brand stem cell supplements for degenerative disease treatment, health improvement, and anti-aging

alps-holdings.com
5Healthcare Financial Solutions
TypeManaged Services
Description

ALPSCap providing innovative healthcare with financial solutions to corporations, governments, and high-net-worth individuals

alps-holdings.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure, Supply Chain
GTM typeB2B and B2C
B2B and B2C
Offering typeServices
Services
Brand1 of 8 records shown
1CelestiaLab
Description

Biotechnology company under ALPS specializing in Preventive Medicine to produce GMP-grade cellular products including mesenchymal stem cells, dental pulp stem cells and induced pluripotent stem cells for regenerative medicine

alps-holdings.com
+7 more records
Core offering1 text field

ALPS is a fully-integrated biotechnology research, medical, and wellness services company that develops and delivers cellular therapies (mesenchymal stem cells, iPSCs, autologous NK cell therapy), genomic and molecular diagnostic testing (whole genome sequencing, mRNA, DNA testing), direct medical and aesthetic services through its medical centre, wellness and anti-aging services, stem cell supplements under the Célébre brand, and healthcare financial solutions via ALPSCap. Its vertically integrated platform spans cGMP-certified research, clinical development, commercialization, and supplementary wellness offerings.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • For early-stage cancer, cure rate can exceed 90-95%, but for advanced cancer it can drop to around 5%
+2 more records
Product and service8 records
1ALPS Medical Centre Services
CategoryMedical and Health Screening Services
2ALPS Wellness Centre and Medical Clinic (Genting Highlands)
CategoryWellness and Anti-Aging Services
3CelestiaLab Cellular Products
CategoryCellular Therapy and Stem Cell Products
4MyGenome Genomic Testing Services
CategoryGenomic and Molecular Diagnostics
5Célébre Stem Cell Supplements
CategoryStem Cell Supplements and Health Products
6ALPSCap Healthcare Financial Solutions
CategoryHealthcare Financial Services
7MontLife Vaccine and Therapeutics Development
CategoryVaccine and Therapeutic Development
8Autologous NK Cell Therapy
CategoryCellular Therapy and Immunotherapy
Description

Cellular therapy service where a patient's own NK cells are purified from blood, cultured with cytokines for three weeks using ALPS' proprietary antibody-free culture protocol, and infused back to eliminate cancer cells and boost the immune system. Clinical safety, tolerability and effectiveness data published in SAGE Open Medical Case Reports.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-20
Description

Partnership to build Bio Valley campus in Johor, Malaysia. The campus will be designed to house upstream research, mid-stream clinical studies, and downstream commercial activities to address gaps in Malaysia's biotech sector.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2024-01-16
Description

Memorandum of Understanding signing for potential collaboration in research and education.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2023-09-26
Description

Courtesy visit to explore potential collaboration opportunity with ALPS in healthcare and wellness educational aspects.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2023-09-17
Description

CanSinoBIO founders visited ALPS headquarters to explore potential strategic partnerships on medical research, clinical trial studies, and gene and cellular therapies. Discussions focused on precision and preventive medicine collaboration.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2023-09-07
Description

Courtesy visit to understand ALPS operations and explore potential strategic research collaboration and placement of medical/biotech students.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2023-08-18
Description

Courtesy visit to explore potential strategic research collaboration and placement of AIMST University's PhD students in ALPS under supervision of ALPS' Chief Scientist.

7Shanghai Moge Biology
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2023-06-09
Description

Malaysia ALPS Medical Center signed contract with Shanghai Moge Biology to jointly invest in construction of Huangshan Medical Healthcare industry, part of RCEP regional cooperation.

alps-holdings.com
8Universiti Sains Malaysia (USM) - Institute of Advanced Medical and Dental Institute (IPPT)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-09-24
Description

Strategic academia-industry collaboration establishing USM-ALPS Heart Research Laboratory. ALPS provided advanced equipment for cardiac cell and molecular research, supporting translational research with next-generation technology.

alps-holdings.com
Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Market position
Competitive moat5 records

Each record includes

Type, Details

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries6 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

ALPS Global Holding Berhad

Biotechnology and Regenerative Medicinealps-holdings.com

ALPS Global Holding Berhad is a Kuala Lumpur-based integrated biotechnology group operating cell and gene therapy manufacturing (CelestiaLab), genomic testing (MyGenome), medical and wellness services, stem cell supplements, and healthcare financial solutions, serving individual patients, medical tourists, and institutional clients in Southeast Asia following its October 2025 Nasdaq listing.

What ALPS Global Holding Berhad does

ALPS Global Holding Berhad is a Kuala Lumpur-based, fully integrated biotechnology research, medical, and wellness services company that operates across predictive, preventive, and precision medicine. Through its wholly-owned subsidiaries, the group runs a cGMP-certified cell and gene therapy facility (CelestiaLab), an MS ISO 15189:2022 accredited molecular laboratory (MyGenome) for whole genome sequencing and related tests, a medical diagnostic and treatment centre (ALPS Medical Centre), a consumer stem-cell supplement brand (Célébre), a healthcare financial solutions unit (ALPSCap), and a vaccine-focused subsidiary (MontLife). Core technology assets include a patent-pending antibody-free NK cell culture protocol (Malaysian patent application PI2025002484) that enables cost-effective, large-scale production of autologous natural killer cells, alongside mesenchymal stem cell (MSC) and induced pluripotent stem cell (iPSC) capabilities.

The company monetizes through professional services across genomic testing and clinical care, one-time licenses/sales of GMP-grade cellular products and stem cell supplements, and managed services via ALPSCap's healthcare financial solutions for corporations, governments, and high-net-worth individuals. Go-to-market combines direct medical service delivery at its Kuala Lumpur and Genting Highlands facilities, medical tourism channels targeting international patients, and B2B partnerships with universities and government institutions, with a stated shift toward captive insurance models and university-affiliated programmes post-Nasdaq listing. Customer segments include patients seeking advanced treatments typically excluded from conventional healthcare, health-conscious individuals pursuing preventive genomic screening, international medical tourism clients, and corporate/institutional buyers of integrated health-wealth solutions.

Following a business combination with Globalink Investment Inc., the US parent (Alps Group Inc.) began trading on Nasdaq under ticker ALPS on October 31, 2025, at an implied enterprise value of approximately US$1.6 billion alongside a modest US$3.1M PIPE financing. The company is unprofitable, with approximately US$3.7M in trailing twelve-month revenue, and has seen its market capitalization decline to roughly US$162 million amid broader early-stage biotech investor caution, while pivoting commercially toward Bio Valley campuses in Johor and Kuala Lumpur, insurance and education verticals, and continued clinical validation of its NK cell pipeline.

ALPS Global Holding Berhad firmographics

Firmographics
Name
ALPS Global Holding Berhad
Legal name
ALPS Global Holding Berhad
Website
https://alps-holdings.com
Company type
Public
Founded year
2015
Operating status
Operating
Headcount range
11–50 employees
Short description
ALPS Global Holding Berhad is a Kuala Lumpur-based integrated biotechnology group operating cell and gene therapy manufacturing (CelestiaLab), genomic testing (MyGenome), medical and wellness services, stem cell supplements, and healthcare financial solutions, serving individual patients, medical tourists, and institutional clients in Southeast Asia following its October 2025 Nasdaq listing.
Ownership category
akta.pro rank

ALPS Global Holding Berhad industry classification

Industry
Product category
Biotechnology and Regenerative Medicine
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Food (Health) Supplement Retailers (456191)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836), Medicinal Chemicals & Botanical Products (2833), Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAGAGAA
Cell Therapy CDMO (Autologous/Allogeneic Manufacturing)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
SECONDARYHLAAALAD
Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics)

Keywords

  • Cellular therapy services
  • Genomic sequencing testing
  • Regenerative medicine research
  • Medical wellness services
  • Stem cell products

Where ALPS Global Holding Berhad is headquartered

Location

Headquarters

HQ city
Kuala Lumpur
HQ country
Malaysia
HQ region
Asia

Offices2 records

Markets served

ALPS Global Holding Berhad business model

Business model
GTM type
B2B and B2C
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

  1. Medical and Wellness Services: Revenue from medical centres, anti-aging clinics, health screening services, and aesthetic treatments
  2. Genomic Testing Services: Whole genome sequencing, mRNA testing, DNA testing services provided through MyGenome subsidiary
  3. Cellular Therapy Products: GMP-grade stem cell products including mesenchymal stem cells, dental pulp stem cells, and iPSCs for therapeutic applications
  4. Stem Cell Supplements: Célebre brand stem cell supplements for degenerative disease treatment, health improvement, and anti-aging
  5. Healthcare Financial Solutions: ALPSCap providing innovative healthcare with financial solutions to corporations, governments, and high-net-worth individuals

Go-to-market motion2 records

Distribution channels4 records

Marketing channels5 records

ALPS Global Holding Berhad product offering

Product offering

Core offering

ALPS is a fully-integrated biotechnology research, medical, and wellness services company that develops and delivers cellular therapies (mesenchymal stem cells, iPSCs, autologous NK cell therapy), genomic and molecular diagnostic testing (whole genome sequencing, mRNA, DNA testing), direct medical and aesthetic services through its medical centre, wellness and anti-aging services, stem cell supplements under the Célébre brand, and healthcare financial solutions via ALPSCap. Its vertically integrated platform spans cGMP-certified research, clinical development, commercialization, and supplementary wellness offerings.

Differentiator

Problem solved

Functional benefit

Brands

  • CelestiaLab: Biotechnology company under ALPS specializing in Preventive Medicine to produce GMP-grade cellular products including mesenchymal stem cells, dental pulp stem cells and induced pluripotent stem cells for regenerative medicine
  • MyGenome
  • ALPS Medical Centre
  • Célebre
  • ALPSCap
  • MontLife
  • ALPS GlobeMedic
  • Bio Valley

Products and services

  • ALPS Medical Centre Services
  • ALPS Wellness Centre and Medical Clinic (Genting Highlands)
  • CelestiaLab Cellular Products
  • MyGenome Genomic Testing Services
  • Célébre Stem Cell Supplements
  • ALPSCap Healthcare Financial Solutions
  • MontLife Vaccine and Therapeutics Development
  • Autologous NK Cell Therapy Cellular therapy service where a patient's own NK cells are purified from blood, cultured with cytokines for three weeks using ALPS' proprietary antibody-free culture protocol, and infused back to eliminate cancer cells and boost the immune system. Clinical safety, tolerability and effectiveness data published in SAGE Open Medical Case Reports.

Quantifiable outcome

  • For early-stage cancer, cure rate can exceed 90-95%, but for advanced cancer it can drop to around 5%
  • +2 more outcomes

Companies that use ALPS Global Holding Berhad

Customer profile

Named customers1 record

Segments4 records

Ideal customer profiles4 records

ALPS Global Holding Berhad technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

ALPS Global Holding Berhad partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered core, minor and flagship.

  • JLand Group (JohorCorp)coreStrategic or Co-development Partner · 20 April 2026Partnership to build Bio Valley campus in Johor, Malaysia. The campus will be designed to house upstream research, mid-stream clinical studies, and downstream commercial activities to address gaps in Malaysia's biotech sector.
  • Xiamen University MalaysiaminorStrategic or Co-development Partner · 16 January 2024Memorandum of Understanding signing for potential collaboration in research and education.
  • HELP UniversityminorStrategic or Co-development Partner · 26 September 2023Courtesy visit to explore potential collaboration opportunity with ALPS in healthcare and wellness educational aspects.
  • CanSino Biologics Inc. (CanSinoBIO)flagshipStrategic or Co-development Partner · 17 September 2023CanSinoBIO founders visited ALPS headquarters to explore potential strategic partnerships on medical research, clinical trial studies, and gene and cellular therapies. Discussions focused on precision and preventive medicine collaboration.
  • IMU UniversityminorStrategic or Co-development Partner · 7 September 2023Courtesy visit to understand ALPS operations and explore potential strategic research collaboration and placement of medical/biotech students.
  • AIMST UniversityminorStrategic or Co-development Partner · 18 August 2023Courtesy visit to explore potential strategic research collaboration and placement of AIMST University's PhD students in ALPS under supervision of ALPS' Chief Scientist.
  • Shanghai Moge BiologyminorStrategic or Co-development Partner · 9 June 2023Malaysia ALPS Medical Center signed contract with Shanghai Moge Biology to jointly invest in construction of Huangshan Medical Healthcare industry, part of RCEP regional cooperation.
  • Universiti Sains Malaysia (USM) - Institute of Advanced Medical and Dental Institute (IPPT)coreStrategic or Co-development Partner · 24 September 2020Strategic academia-industry collaboration establishing USM-ALPS Heart Research Laboratory. ALPS provided advanced equipment for cardiac cell and molecular research, supporting translational research with next-generation technology.

Scale indicators7 records

Recent moves8 records

Expansion highlights6 records

ALPS Global Holding Berhad competitors and assessment

Company assessment

Market position

Competitive moat5 records

Key highlights7 records

Customer concentration

ALPS Global Holding Berhad social profiles

Digital presence

ALPS Global Holding Berhad financial estimates

Financial estimate

Revenue estimate

Valuation estimate

ALPS Global Holding Berhad leadership team

Management profile

Number of profiles

Profiles4 records

ALPS Global Holding Berhad subsidiaries and ownership

Company hierarchy

Subsidiaries6 records

ALPS Global Holding Berhad funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

ALPS Global Holding Berhad M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ALPS Global Holding Berhad

What does ALPS Global Holding Berhad do?

ALPS is a fully-integrated biotechnology research, medical, and wellness services company that develops and delivers cellular therapies (mesenchymal stem cells, iPSCs, autologous NK cell therapy), genomic and molecular diagnostic testing (whole genome sequencing, mRNA, DNA testing), direct medical and aesthetic services through its medical centre, wellness and anti-aging services, stem cell supplements under the Célébre brand, and healthcare financial solutions via ALPSCap. Its vertically integrated platform spans cGMP-certified research, clinical development, commercialization, and supplementary wellness offerings.

Is ALPS Global Holding Berhad a public or private company?

ALPS Global Holding Berhad is a public company. It is classified as public and is currently operating.

When was ALPS Global Holding Berhad founded?

ALPS Global Holding Berhad was founded in 2015. It employs 11 to 50 people.

Where is ALPS Global Holding Berhad based?

ALPS Global Holding Berhad is headquartered in Kuala Lumpur, Malaysia, in the Asia region.

How does ALPS Global Holding Berhad make money?

Five revenue lines are on record. Medical and Wellness Services are the primary driver. The others are genomic Testing Services, cellular Therapy Products, stem Cell Supplements and healthcare Financial Solutions.

Does ALPS Global Holding Berhad have an API?

No public API is recorded for ALPS Global Holding Berhad.

What industry is ALPS Global Holding Berhad in?

ALPS Global Holding Berhad's product category is Biotechnology and Regenerative Medicine. Its primary akta.pro industry code is HLAGAGAA, Cell Therapy CDMO (Autologous/Allogeneic Manufacturing), with a secondary code of HLAAALAD, Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics). Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
AInvestShould You Invest in the ALPS Medical Breakthroughs ETF (SBIO)?The ALPS Medical Breakthroughs ETF (SBIO) is a passively managed healthcare ETF launched in 2014, tracking the Poliwogg Medical Breakthroughs Index. It holds about 107 small- and mid-cap biotech stocks, with Crinetics and Apogee as top holdings, and has returned 82.83% over the past year. The fund carries a Zacks ETF Rank of 3 (Hold).Business InsiderNBiOSHOWCASE 2024 Announces First Biotech Unicorn In Malaysia, Attracts Nearly RM3 Billion Foreign InvestmentALPS Global Holding Berhad was announced as Malaysia's first biotech unicorn at the NBiOSHOWCASE 2024 summit, with a Nasdaq listing expected in Q4 2024 at an enterprise value of about US$1.6 billion. Biocon has committed nearly RM3 billion in investment, including an insulin manufacturing facility expected to operate by 2026.TNGlobalMalaysia welcomes its second unicorn, NASDAQ-bound biotech firm ALPS Global Holdings BhdALPS Global Holding Bhd has achieved unicorn status with an enterprise value of approximately $1.6 billion and is expected to list on NASDAQ in the fourth quarter following a merger with Globalink Investment Inc. This milestone marks it as Malaysia's second unicorn company and aligns with national biotechnology policy objectives. The announcement coincided with the National Bioeconomy Exhibition 2024, where significant memoranda of understanding were signed to strengthen the local industry.NasdaqALPS GLOBAL HOLDING BERHAD TO BECOME PUBLICLY TRADED THROUGH PROPOSED MERGER WITH GLOBALINK INVESTMENT INC.Alps Global Holding Berhad and Globalink Investment Inc. entered a definitive merger agreement to combine into Alps Life Science Inc., expected to list on Nasdaq. The transaction values Alps at an enterprise value of approximately US$1.6 billion and is expected to close in Q2 2024.GlobeNewswireALPS GLOBAL HOLDING BERHAD TO BECOME PUBLICLY TRADED THROUGH PROPOSED MERGER WITH GLOBALINK INVESTMENT INC.Alps Global Holding Berhad and Globalink Investment Inc. entered a definitive merger agreement, valuing Alps at an enterprise value of approximately US$1.6 billion. The combined company, named Alps Life Science Inc., is expected to be listed on Nasdaq in Q2 2024. The deal includes an earn-out provision for up to 48 million additional shares.GlobeNewswireALPS GLOBAL HOLDING BERHAD TO BECOME PUBLICLY TRADED THROUGH PROPOSED MERGER WITH GLOBALINK INVESTMENT INC.Alps Global Holding Berhad and Globalink Investment Inc. entered a definitive merger agreement, valuing Alps at an enterprise value of approximately US$1.6 billion. The combined company, named Alps Life Science Inc., is expected to be listed on Nasdaq in Q2 2024. The deal includes an earn-out provision for up to 48 million additional shares.BloombergSouth African Cannabis Firm Wins Malaysian Backer in New Listing BidCilo Cybin Holdings, a South African medical cannabis firm, plans a new listing bid with Malaysian biotech firm ALPS Global. ALPS will underwrite a SPAC with 54 million rand ($3 million) and take a majority stake, aiming to list in Johannesburg by mid-year.Bloomberg Law NewsS. Africa Cannabis Firm Wins Malaysian Backer in New Listing BidCilo Cybin Holdings, a South African medical cannabis firm, plans to list via a SPAC underwritten by Malaysian biotech firm ALPS Global. ALPS will underwrite 54 million rand ($3 million) and take a majority stake, aiming to list in Johannesburg by mid-year.EngineeringnewsSouth African cannabis firm wins Malaysian backer in new listing bidCilo Cybin, a South African medical cannabis firm, plans to list via a SPAC underwritten by Malaysian biotech ALPS Global. ALPS will take an 85% stake, with the public holding 10% and founder Gabriel Theron the balance. The SPAC will buy Cilo Cybin's existing pharmaceutical unit, and ALPS aims to list on Nasdaq by year-end.Utusan MalaysiaPusat rawatan kanser Sabah jalin kerjasama strategik teknologi mRNAALPS Medical Centre will partner with Sabah state government to offer mRNA-based treatment for chronic diseases, including cancer. The technology, which has set records in China and Singapore, aims to address treatment gaps in Sabah. ALPS also offers whole genome sequencing and stem cell services.